News | May 14, 2009

CMS Opens NCD for PET-FDG used in Cervical Cancer Staging

May 14, 2009 -On May 8, 2009, CMS opened the reconsideration of the National Coverage Determination (NCD) on Positron Emission Tomography (FDG). The requestors have asked CMS to reconsider the NCD and broaden national coverage of FDG-PET (without CED restrictions) for the staging of cervical cancer (i.e. in those women who have been diagnosed with cervical cancer but who do not otherwise meet the coverage criteria). The requestors also ask that the use of FDG-PET be nationally noncovered to make the diagnosis of cervical cancer, as this imaging is not helpful to make the initial diagnosis.

Currently, Medicare covers, nationally, FDG-PET when it is used by the beneficiary’s physician to guide the subsequent management of cervical cancer in women who have undergone anticancer treatment. For example, FDG-PET is covered to determine whether or not the cancer has responded to treatment or to determine if the patient's symptoms are being caused by a recurrence or spreading of the cancer.

Additionally, FDG-PET is nationally covered for some uses in women diagnosed with cervical cancer who have not yet received anticancer treatment. Specifically, FDG-PET imaging is covered as an adjunct test for the detection of pre-treatment metastasis (i.e., staging) in newly diagnosed cervical cancers following conventional imaging that is negative for extra-pelvic metastasis.

Medicare coverage of all other uses of FDG-PET related to cervical cancer is restricted to beneficiaries who are enrolled in a prospective clinical study under a CED program, like NOPR.

Follow the link to see the NCA Tracking Sheet for Positron Emission Tomography (FDG) for Cervical Cancer (CAG-00181R2)

There will be a public comment period open from 5/8/2009 – 6/7/2009. To submit comments, go to this link:

CMS considers all public comments, and is particularly interested in clinical studies and other scientific information relevant to the technology under review.

CMS expects to release the proposed decision memo on November 8, 2009 and finalize their decision by February 6, 2010.

For more information: and

Related Content

Siemens Healthineers Announces First U.S. Install of Biograph Vision PET/CT
News | PET-CT | March 06, 2019
Siemens Healthineers’ new Biograph Vision positron emission tomography/computed tomography (PET/CT) system has been...
News | PET-CT | February 06, 2019
Technological advancements in positron emission tomography/computed tomography (PET/CT) offer both clinicians and pat
FDA Clears United Imaging Healthcare uExplorer Total-Body Scanner
Technology | PET-CT | January 23, 2019
January 23, 2019 — United Imaging Healthcare (United Imaging) announced U.S.
Mirada Medical Joins U.K. Consortium Exploring Healthcare AI
News | Artificial Intelligence | December 04, 2018
Mirada Medical, a leading global brand in medical imaging software, will form part of an artificial intelligence (AI)...
Siemens Healthineers Showcases syngo Virtual Cockpit for More Flexible Workforce Management
News | Teleradiology | November 25, 2018
During the 104th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA), Nov. 25-30...
Bruker Introduces New High-Performance Preclinical PET/CT Si78 System
Technology | PET-CT | September 26, 2018
September 26, 2018 — Bruker recently announced the introduction of the new preclinical...
Siemens Healthineers Announces FDA Clearance of syngo.via VB30 Molecular Imaging Software
Technology | Nuclear Imaging | July 16, 2018
At the 2018 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), June 23-26 in Philadelphia...
Philips North America and GE Healthcare Win IMV PET Imaging ServiceTrak Awards
News | PET Imaging | June 25, 2018
IMV, part of the Science and Medicine Group and a market research and business intelligence provider to the imaging...
FDA Clears New Imaging Functionalities for Biograph mCT PET/CT Systems
Technology | PET-CT | June 21, 2018
Siemens Healthineers will announce U.S. Food and Drug Administration (FDA) clearance of four new system features for...